Oxford / AstraZeneca Coronavirus vaccine New data suggest that the risk of some bleeding disorders may increase slightly, but such cases are extremely rare and the benefits of the vaccine continue to outweigh the risks, researchers say. Stated.
Analysis of people who received the first dose of Oxford / AstraZeneca or Pfizer / BioNTech Vaccine We found a slight increase in the risk of an autoimmune hemorrhagic condition known as immune thrombocytopenic purpura (ITP) associated with the Oxford / AstraZeneca vaccine. Blood coagulation syndrome It was previously linked to the vaccine.
In ITP, the immune system destroys platelets, blood cells that help blood clot. This condition can cause mild bruising in some people and can cause excessive bleeding and long-term illness in others, but the symptoms are usually mild and death from ITP is extremely rare.
It is estimated to occur in about 11 people for every 1 million people who receive the vaccine for the first time.
Aziz Sheikh and colleagues at the University of Edinburgh in the United Kingdom state that these very small risks are important but rare and are comparable to the risks of other jabs, including: vaccine For hepatitis B, measles, mumps, rubella, and flu.
They emphasize the need to understand the findings in the context of the obvious benefits of the Oxford / AstraZeneca vaccine. The risk of developing serious vaccine-related adverse events is much lower than the risk of serious illness or death caused by the coronavirus, especially for the elderly and other vulnerable populations.
Further research is needed to involve young people and evaluate their response to a second dose of the vaccine.
“The overall message is that the risk of ITP for the Oxford / AstraZeneca vaccine is high, but the benefits outweigh the risks,” said the London School of Hygiene and Tropical Medicine, which was not involved in the study. Stephen Evans said. .. “For the vast majority of people, ITP does not cause serious problems, but it does not apply to everyone.”
The study investigated cases of vaccine-related bleeding and cardiovascular disease in 2.53 million adults in Scotland who received their first vaccine between December 2020 and April 2021.
Researchers have found that for these people, Oxford / AstraZeneca jabs are associated with a slight increase in the risk of ITP until 27 days after vaccination.
The analysis also found that up to 27 days after vaccination, the risk of other jab-related arterial blood clots and bleeding events was significantly increased.
However, there were insufficient data to determine if there was an association between the Oxford / AstraZeneca vaccine and cerebral venous sinus thrombosis, a rare condition in which blood clots form in the brain.
There was no evidence of an increased risk of adverse events associated with the Pfizer / BioNTech vaccine.
Clinical trial Although few reports of serious side effects have been reported, Pfizer / BioNTech and Oxford / AstraZeneca vaccines have generally proven to be well tolerated.
The UK Medicines and Healthcare Products Regulatory Authority received 209 reports of bleeding and thrombotic disorders after the 22 million first and 6.8 million second doses of Oxford / AstraZeneca jab.
Since May, people under the age of 40 have been offered in the UK Alternative vaccine When possible in light of the rare risk of blood coagulation syndrome.
Journal reference: Natural medicine, DOI: 10.1038 / s41591-021-01408-4
Sign up for our free Medical checkup Newsletter for a summary of all health and fitness news you need to know, every Saturday
Details of these topics:
AstraZeneca covid-19 vaccine can rarely interfere with blood clotting
Source link AstraZeneca covid-19 vaccine can rarely interfere with blood clotting